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Background: In order to confirm the roles of creatine (Cr) in epilepsy, we investigated the anti-convulsive effects
of Cr, creatine transporter (CRT) and creatine kinases (CKs) against chemical-induced acute seizure activity and
chronic epileptic seizure activity.
Results: Two hr after pilocarpine (PILO)-seizure induction, ubiquitous mitochondrial CK (uMtCK) immunoreactivity
was unaltered as compared to control level. However, brain-type cytoplasm CK (BCK) immunoreactivity was
decreased to 70% of control level. CRT immunoreactivity was decreased to 60% of control level. Following Cr or
Tat-CK treatment, uMtCK or CRT immunoreactivity was unaffected, while BCK immunoreactivity in Cr treated group
was increased to 3.6-fold of control levels. b-Guanidinopropionic acid (GPA, a competitive CRT inhibitor) reduced
BCK and CRT expression. In addition, Cr and tat-BCK treatment delayed the beginning of seizure activity after PILO
injection. However, GPA treatment induced spontaneous seizure activity without PILO treatment. In chronic
epilepsy rats, both uMtCK and CRT immunoreactivities were reduced in the hippocampus. In contrast, BCK
immunoreactivity was similar to that observed in control animals. Cr-, GPA and tat-BCK treatment could not
change EEG.
Conclusion: Cr/CK circuit may play an important role in sustaining or exacerbating acute seizure activity, but not
chronic epileptic discharge.
Background
Maintenance of energy homeostasis in the brain requires a
distinct molecular circuitry which provides tight coupling
between energy consumption and production during the
performance of sensory, motor and cognitive processes
[1,2]. It is generally assumed that most energy required in
the nervous system is provided in the form of adenosine
triphosphate (ATP) by mitochondria [3]. ATP production
by glycolysis in glia [4] and neurons has been recognized
as an alternative source of energy [5,6]. Furthermore, local
ATP/ADP ratios and proper distribution of metabolic
energy are maintained by catalyzed exchange of high-
energy phosphoryls between g-ATP and phosphocreatine
(PCr) or b-adenosine diphosphate (b-ADP) [7,8].
The brain is a main target in infants with creatine (Cr)-
deficiency syndrome; the patients exhibit delayed psycho-
motor development, hypotonia, seizure and myelination
delay [9-13]. Cr biosynthesis involves tow sequential
steps catalyzed by L-arginine:glycine amidiontransferase
(AGAT) and S-adenosylmethionine:guanidinoacetate N-
methyltransferase (GAMT). Cr is mainly synthesized in
the liver and pancreas [14], and continuously transported
to the brain via creatine transporter (CRT) across the
blood-brain barrier [15]. Cr is also synthesized in the
brain [16]. Astrocytes have been shown to synthesize
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any medium, provided the original work is properly cited.creatine from glycine added to culture media [17]. Phos-
phate transfer reaction between Cr and PCr is reversibly
catalyzed by creatine kinases (CKs) present in the mito-
chondria and cytoplasm [18]. Four CK isozymes have
been identified, ubiquitous mitochondrial CK (uMtCK),
sarcomeric mitochondrial CK, brain-type cytoplasm CK
(BCK) and muscle-type cytoplasmic CK [14]. In the
brain, uMtCK and BCK are expressed. CK reaction
(MgATP2
- +C r↔ MgADP
- +P C r 2
- +H
+) plays an
important role in regulation of PCr tissue level upon phy-
siological stimulation [19]. Thus, CKs have an energy
protective role in the brain. Cr feeding increases survival
under experimentally stressed, hypoxic/ischemic condi-
tions [20,21]. Furthermore, PCr/Cr loading has been
demonstrated by showing beneficial effects of Cr-feeding
in children with inborn errors in Cr transport [22].
On the other hand, ATP metabolic rates in cerebral
hemisphere, including cerebral blood flow as well as ana-
bolic and aerobic glycolysis increase two to three times
during seizures [21]. It has been also reported that seizure
decreases total glycogen level to 60%, and increases lactate
to more than sevenfold as compared to pre-ictal condition
[23]. However, the levels of ATP and glucose did not
change [23] and energy homeostasis was maintained [24].
Thus, seizures seem to provoke coupling of CK activity
rather than glucose and oxygen consumption. However,
the roles of CK in seizure activity are still controversial.
Pentylenetetrazol (PTZ)-induced seizure activity increases
local cerebral glucose utilization [25], a higher CK rate
constant and a high ATP turnover [26]. However, BCK
knockout (KO) mice have showed significantly more myo-
clonic jerks, while slower chemically induced seizure
development [27]. Furthermore, Eraković et al. [28] have
also reported that lithium-pilocarpine-induced status
epilepticus does not influence CK activity. Therefore, the
present study was undertaken to evaluate the potential
anti-convulsive effects of Cr, creatine transporter and crea-
tine kinases against in chemical-induced acute seizure
activity and chronic epileptic seizure activity
Methods
Experimental animals and chemicals
This study utilized the progeny of Sprague-Dawley (SD)
rats (male, 9 weeks old) obtained from Experimental
Animal Center, Hallym University, Chunchon, South
Korea. The animals were provided with a commercial
diet and water ad libitum under controlled temperature,
humidity and lighting conditions (22 ± 2°C, 55 ± 5%
and a 12:12 light/dark cycle with lights). The procedures
involving animals and their care were conducted in con-
formity with the institutional guidelines and in compli-
ance with international laws and policies (NIH Guide
for the Care and Use of Laboratory Animals, NIH
Publication No. 80-23, 1996). All reagents were obtained
from Sigma-Aldrich (St. Louis, MO), except as noted.
Drug treatment
Animals were injected intraperitoneally with saline, Cr
(200 mg/kg, I.P.) or b-guanidinopropionic acid (GPA, a
competitive creatine transporter inhibitor, 400 mg/kg,
I.P.) once in everyday at 7 days before experimental pro-
cedures [29-32]. The dosage of drugs was chosen based
on the preliminary study.
Construction and purification of Tat-BCK fusion proteins
To generate a cell-permeable expression vector, Tat-
BCK, and CK cDNA was subcloned into the pET-15b
plasmid that had been reconstructed to contain the Tat
peptide. The Tat-BCK expression vector thus formed
contained consecutive cDNA sequences encoding BCK,
HIV-1 Tat peptide and six histidine residues at the
amino-terminus. We also constructed the BCK expres-
sion vector to produce control BCK protein without Tat
transduction peptides (data not shown). Following the
induction of expression, the Tat-BCK fusion proteins
were purified. The fusion proteins were expressed in
E. coli and the clarified cell extracts were loaded onto a
Ni
2+-nitrilotriacetic acid sepharose affinity column.
Fusion protein containing fractions was combined and
salts were removed using a PD10 column [33].
Western blot analysis
To evaluate efficiency of Tat-BCK transduction, animals
were injected intraperitoneally Tat-protein, BCK or Tat-
BCK (15 mg/kg, n = 3, respectively). One hr after injec-
tion, animals were used in Western blot study. After sacri-
fice and removal of hippocampi, the tissues were
homogenized in 50 mM HEPES (pH 7.4), 0.1 mM EGTA
(pH 8.0), 0.2% NP-40, 10 mM EDTA (pH 8.0), 15 mM
sodium pyrophosphate, 100 mM h-glycerophosphate, 50
mM NaF, 150 mM NaCl, 2 mM sodium orthovanadate, 1
mM PMSF, and 1 mM DTT. After centrifugation at
15,000 g, the protein concentration was determined in the
supernatants by using the Micro BCA protein assay kit
with bovine serum albumin as the standard (Pierce Che-
mical, Rockford, IL, USA). Aliquots containing 50 μg total
proteins were boiled in loading buffer containing 150 mM
Tris (pH 6.8), 3 mM DTT, 6% SDS, 0.3% bromophenol
blue, and 30% glycerol. Then, each aliquot was loaded
onto a 12% polyacrylamide gel. After electrophoresis, the
gels were transferred onto nitrocellulose transfer mem-
branes (Schleicher and Schuell, Keene, NH, USA). The
membrane was blocked in 5% nonfat milk in Tris-buffered
saline (TBS; 20 mM Tris, 0.2 M NaCl, pH 7.5) containing
0.05% tween-20 (TBST) for 2 h and was then incubated
for 1 h at room temperature with anti-histidine antibody
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1 h with a proper secondary antibody conjugated to horse-
radish peroxidase diluted 1:10000 in TBST. The mem-
brane was incubated with a chemiluminescent substrate
and exposed to Hyperfilm ECL (Amersham Biosciences,
Piscataway, NJ, USA) [34-36]. As the results, histidine
immunoband was detected in the Tat-BCK injected ani-
mals (Figure 1B).
Acute seizure and chronic epilepsy model
Rats were treated with pilocarpine (PILO, 380 mg/kg, i.p.)
at 20 min after methylscopolamine (5 mg/kg, i.p.) and
were placed in individual observation chambers where sei-
zure activity was scored according to the system of Racine
[37]. Animals that entered SE typically did so within 10 to
30 min of the administration of PILO and exhibited con-
tinuous seizure activity of between 2 and 5 on the Racine
scale. For acute seizure models, animals were anesthetized
(urethane, 1.5 g/kg, I.P.) and perfused via the ascending
aorta with 200 ml of 4% paraformaldehyde in phosphate
buffer (see tissue processing and immunohistochemistry)
at 2 hr after PILO injection (N = 5, respectively). For
chronic epilepsy model, diazepam (10 mg/kg, i.p.) was
administered 2 hrs after onset of SE and repeated, as
needed. Following SE, animals were observed 3 - 4 hrs a
day in the vivarium for general behavior and occurrence of
spontaneous seizures for 4 weeks. The onset of sponta-
neous seizure occurrence was approximately 3 - 4 weeks
after SE (n = 5, respectively). Spontaneous seizures were
scored grade 3 or greater on the Racine [37] scale (i.e.,
forelimb clonus ± rearing ± falling). These behavioral
results were consistent with our previous studies [38,39].
Control animals were treated as for experimental animals,
but received saline in place of PILO. In addition, 30 min
before PILO treatment, diazepam (10 mg/kg, i.p.) was
given to some animals. Diazepam pretreatment completely
prevented SE. The PILO or saline treatment was per-
formed in the same day. Age matched rats were used as
controls. Data from every group of control animals were
pooled because there was no difference between groups.
Electrophysiology
Rats were anesthetized (urethane, 1.5 g/kg, I.P.) and
placed in a stereotaxic frame. Holes were drilled through
the skull to introduce electrodes. The coordinates (in
mm) were as follows. For the recording electrode (to the
dentate gyrus): - 3.8 anterior-posterior, 2.5 lateral to
bregma, 2.9 depth, at a right angle to the skull surface.
For the stimulating electrode (to the angular bundle):
4.2 lateral to lambda, 3.0 depth. Stainless steel electrode
(Plastics One Inc, USA) was used for recording. The
reference electrode was placed in the posterior cranium
over the cerebellum. Signals were recorded with DAM
80 differential amplifier (0.1-3000 Hz bandpass, World
Precision Instruments, USA) and data were digitized
(20 kHz) and analyzed on MacChart 5 (AD Instruments,
Australia). After establishing a stable baseline for at least
30 min, PILO (380 mg/kg, I.P.) were given at 20 min
after methylscopolamine (5 mg/kg, i.p.), and observed
the latency (n = 5, respectively). Some animals were
injected intraperitoneally with tat-BCK or tat-protein
(15 mg/kg, I.P., respectively, n = 5, respectively) after
baseline recording. The dosage of tat-BCK was chosen
based on the preliminary study. Thirty min after admin-
istration, PILO (380 mg/kg, I.P.) were given at 20 min
after methylscopolamine (5 mg/kg, i.p.), and observed
the latency. The latency was determined as seconds
f r o mt h eP I L Oi n j e c t i o nt i m ep o i n tt ot h et i m ep o i n t
showing the first seizure activity [40]. The same method
was applied to chronic epilepsy rats without PILO and
methylscopolamine treatments. To analyze changes in
EEG power value in chronic epilepsy, root mean square
(RMS) value was measured during the baseline and
post-tat-BCK treatment measurements.
Tissue processing and immunohistochemistry
Animals were anesthetized (urethane, 1.5 g/kg, I.P.) and
perfused via the ascending aorta with 200 ml of 4% par-
aformaldehyde in phosphate buffer. Control animals
were also perfused with the same method. The brains
were removed, postfixed in the same fixative for 4 h,
and rinsed in PB-containing 30% sucrose at 4°C for 2
days. Thereafter, the tissues were frozen and sectioned
with a cryostat at 30 μm, and consecutive sections were
collected in six-well plates containing phosphate buf-
fered saline (PBS). These free-floating sections were first
incubated with 10% normal horse serum for 30 min at
room temperature. They were then incubated in the
rabbit anti-BCK(Santa Cruz, USA, diluted 1:200),
uMtCK (Santa Cruz, USA, diluted 1:200) or CRT
(Abcam, UK, diluted 1:200) in PBS containing 0.3% tri-
ton X-100 and 2% normal chicken serum overnight at
room temperature. After washing three times for
10 min with PBS, sections were incubated sequentially,
in secondary antibody and ABC complex (Vector, USA),
diluted 1:200 in the same solution as the primary anti-
serum. Between the incubations, the tissues were
washed with PBS three times for 10 min each. The sec-
tions were visualized with 3,3’-diaminobenzidine (DAB)
in 0.1 M Tris buffer and mounted on the gelatin-coated
slides. The immunoreactions were observed under the
Axioscope microscope (Carl Zeiss, Germany). For dou-
ble immunofluorescent study, sections were then incu-
bated in a mixture of rabbit anti-BCK(Santa Cruz, USA,
diluted 1:100) or CRT (Abcam, UK, diluted 1:100)/
mouse anti-GFAP IgG (Chemicon, USA, diluted 1:4 k)
in PBS containing 0.3% triton X-100 overnight at room
temperature. After washing three times for 10 minutes
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Page 3 of 12Figure 1 Changes in uMtCK (A, B), BCK (C, D) and CRT (E, F) immunoreactivity in the rat hippocampus at 2 hr after PILO injection: (A,
C, E) saline-treated animal; (B, D, F) PILO-treated animal. uMtCK immunoreactivity is unaffected by PILO-induce seizure activity. However,
both BCK and CRT immunoreactivities are markedly reduced in the rat hippocampus at 2 hr after PILO injection. Rectangles in panels 1 indicate
the regions of panels 2 and 3. Bar = 200 (panel 1) and 25 (panels 2-4) μm.
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FITC- and Cy3-conjugated secondary antiserum (1:250,
Amersham, USA) for 2 hr at room temperature. The
sections were washed three times for 10 min with PBS,
and mounted on gelatin-coated slides. For nuclei coun-
terstaining, we used Vectashield mounting medium with
DAPI (Vector, USA). All images were captured using an
Axiocam HRc camera and Axio Vision 3.1 software. To
establish the specificity of the immunostaining, a nega-
tive control test was carried out with preimmune serum
instead of primary antibody. The negative control
resulted in the absence of immunoreactivity in any
structures. All experiment procedures in this study were
performed under the same circumstance and in parallel.
Quantification of data and statistical analysis
Sections (5 sections per each animal) were viewed
through a microscope connected via a CCD camera to a
PC monitor. For quantification of immunohistochemical
data, images of each section (including the molecular
layer and the granule cell layer of the DG) on the moni-
tor were captured. The mean gray value and its standard
deviation were obtained from the selected images in
Adobe Photoshop 8.0. Each image was normalized by
assessing the mean gray value. After regions (CA1, 3
pyramidal cell layers and dentate granule cell layer)
were outlined, 10 areas per rat (300 μm
2/area) were
then selected from the hippocampus, and this area was
used for analysis. The images were analyzed by convert-
ing all immunolabeled elements that fall within a
threshold range into pure black pixels, and the rest of
the image is converted into pure white pixels. Then per-
centage of pure black and white pixels was calculated.
After this, the integral signal intensity values were
divided by the corresponding area (300 μm
2), and the
average of optical density was calculated. Values of
background staining were obtained from the corpus cal-
losum. Optical density values obtaining from immuno-
histochemistry were corrected by subtracting the
average values of background noise obtained from five
image inputs. The optical density was then standardized
by setting the threshold levels. Intensity measurements
were represented as the mean number of a 256 gray
scale (using NIH Image 1.59 software). All data were
analyzed using Student t-test or one-way analysis of var-
iance (ANOVA) test to determine statistical significance.
Bonferroni’s test was used for post hoc comparisons.
The statistical tests relied on comparison of each time
point to a pool of all time points from saline-treated
controls (because there was no difference between these
control time points). All values were expressed as mean
± SEM. A P-value below either 0.01 or 0.05 was consid-
ered statistically significant [34-36].
Results
The effects of PILO-induced seizure activity on CK and
CRT expressions in the rat hippocampus
In saline-treated animals, uMtCK immunoreactivity was
observed in CA1-3 pyramidal cells, dentate granule cells
and hilar neurons (Figures 1A). One day after SE, uMtCK
immunoreactivity was unaltered as compared to control
level (Figures 1B). In saline-treated animals, BCK immu-
noreactivity was noticeably absent in pyramidal cells and
dentate granule cells, while its immunoreactivity was
obviously detected in some glial component and in a small
subpopulation of hilar neurons (Figures 1C). Double
immunofluorescent study revealed that BCK positive glial
component was astrocytes (data not shown). One day after
SE, BCK immunoreactivity in astrocytes was decreased to
70% of control level (P < 0.01 vs. control, Figures 1D). In
saline-treated animals, CRT immunoreactivity was mainly
observed in dentate granule cells, hilar neurons and CA3
pyramidal cells (Figures 1E). One day after SE, CRT
immunoreactivity in dentate granule cells and CA3 pyra-
midal cells was decreased to 76 and 52% of control level,
respectively (P < 0.05 vs. control, Figures 1F).
The effects of Cr, GPA and tat-BCK on CK and CRT
expressions in the rat hippocampus
uMtCK immunoreactivity was unaffected by Cr, GPA or
tat-BCK treatment, as compared to saline or tat-protein
treatment (Figures 2A-D). As compared to controls
(Figures 3A), BCK immunoreactivity in Cr treated group
was increased to 3.6-fold of control levels (Figures 3B,
P < 0.01). However, BCK immunoreactivity in GPA trea-
ted animals was noticeably absent in the hippocampus
(Figures 3C, P < 0.01). Similar to Cr treated animals,
tat-BCK treatment enhanced BCK immunoreactivity in
astrocytes to 2.6 fold of control levels (Figures 3D, P <
0.05). In addition, a few granule cells and interneurons
showed BCK immunoreactivity following tat-BCK treat-
ment (Figures 3D). CRT immunoreactivity was unaf-
fected by Cr or tat-BCK treatment, as compared to saline
or Tat-protein treatment (data not shown). However,
CRT immunoreactivity in GPA treated animals
was noticeably absent in the hippocampus (Figures 3E,
P < 0.01).
The effects of Cr, GPA and tat-BCK on PILO-induced
seizure activity in the rat hippocampus
In control (saline-treated) animals, PILO induces epilep-
tiform discharges at 598 s after PILO injection (I.P.).
Tat-protein treatment could not affect PILO-induced
seizure activity (data not shown). However, Cr and tat-
BCK treatment delays the beginning of epileptiform dis-
charges up to 1236 s or 1598 s after PILO injection,
respectively (P < 0.05). Thus, Cr and Tat-BCK treatment
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compared with controls, respectively. GPA treatment
induced spontaneous seizure activity without PILO
treatment (Figures 4).
CK and CRT expressions in the hippocampus of chronic
epilepsy rat
In chronic epilepsy rats, uMtCK immunoreactivity was
markedly reduced in CA1-3 pyramidal cells and hilar
neurons due to massive neuronal loss (Figures 5A). In
contrast, BCK immunoreactivity was similar to that
observed in control animals (Figures 5B). Similar to
uMtCK, CRT immunoreactivity was markedly reduced
in CA3 pyramidal cells (Figures 5C). In contrast to non-
SE induce animals (Figures 5D), CRT immunoreactivity
was detected in reactive astrocytes within the stratum
radiatum of the CA1 subfields (Figures 5E).
The effects of Cr, GPA and Tat-BCK on chronic seizure
activity
In chronic epilepsy rats, spontaneous synchronized spik-
ing was detected in EEG, and long-lasting ictal dis-
charges were observed intermittently and irregularly at
least once over the 10 min recording periods. Saline-
and tat-protein treatment could not affect EEG. In addi-
tion, Cr-, GPA and tat-BCK treatment could not change
EEG patterns (Figures 6) or RMS values (data not
shown).
Discussion
Although multiple CK isoforms are expressed in brain
[41-44], little is known regarding the localization of
these isoforms of the functional role for CK in brain.
Indeed, it has been reported that expressions of CKs in
the brain are detected in astrocytes [45], in neurons and
Figure 2 The effect of Tat-protein (A), Cr (B), GPA (C) or Tat-BCK (D) treatment on uMtCK immunoreactivity in the rat hippocampus.
uMtCK immunoreactivity is unaltered after Tat-protein, Cr, GPA or Tat-BCK treatment. Rectangles in panels 1 indicate the regions of panels 2 and
3. Bar = 200 (panel 1) and 25 (panels 2-4) μm.
Kim et al. BMC Neuroscience 2010, 11:141
http://www.biomedcentral.com/1471-2202/11/141
Page 6 of 12astrocytes [46], and in nuclei of glial cells [47]. In the
present study, uMtCK immunoreactivity was observed
in CA1-3 pyramidal cells, dentate granule cells and hilar
neurons. In contrast, astrocytes and a small subpopula-
tion of hilar neurons showed BCK immunoreactivity. In
addition, CRT immunoreactivity was observed in den-
tate granule cells and CA3 pyramidal cells. These find-
ings are agreement with a previous study demonstrating
the localization of CKs and CRT in the rat hippocampus
[48,49].
Seizure activity is one of the acute high-energy
demand situations showing an increase in local cerebral
glucose utilization [25], a higher CK rate constant and a
high ATP turnover [26]. Therefore, Cr and CKs would
play a role in providing a large amount of energy to be
required for seizure progression. In the present study,
Figure 3 The effect of Tat-protein (A), Cr (B), GPA (C, E) or Tat-BCK (D) treatment on BCK (A-D) or CRT (E) immunoreactivity in the rat
hippocampus. As compared to controls, Cr or Tat-BCK treatment increased BCK immunoreactivity in the rat hippocampus. GPA treatment
reduced BCK and CRT immunoreactivity in ther at hippocampus. Rectangles in panels 1 indicate the regions of panels 2 and 3. Bar = 200 (panel
1) and 25 (panels 2-4) μm.
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lowing acute seizure, while uMtCK immunoreactivity
was unaltered. Considering a slower chemically induced
seizure development in BCK KO mice [27], these find-
ings are simply indicated that reduced BCK immunor-
eactivity would be a compensatory response for seizure
activity. However, the present study showed that BCK
expression was mainly detected in hilar interneurons,
which are vulnerable to seizure-induced insults [38]. It
has been reported that PILO injection induces astroglial
degeneration in the molecular layer of the dentate gyrus
[34,35,50]. Furthermore, these alterations are accompa-
nied by neuronal excitability [38,50]. Therefore, our
findings reveal that reduced BCK immunoreactivity
induced by PILO may result in dysfunction of hilar
interneurons and astrocyte, or at least indicate decreases
in their activity. The fast-spiking capability play a role in
the responsiveness of inhibitory neurons [51-56]. There-
fore, it is conceivable that reduced BCK expression/
activity may result in a loss of fast-firing capability to
allow the development of uncontrolled discharges.
Furthermore, it is noteworthy that astroglial activity can
change electrophysiological properties in a synaptic
transmission independent manner: enhanced astroglial
glutamate release, reduced glutamate reuptake, reduc-
tions of glutamine synthase and glutamate dehydrogen-
ase, and impaired K
+ buffering in response to seizure
activity [38,57-60]. Taken together, these reports led us
to speculate on a possible enhanced seizure activity
induced by reduced BCK expression/activity in hilar
interneurons and astrocytes. In the present study, indeed
Cr or tat-BCK treatment reduced PILO-induced acute
seizure susceptibility. In addition, GPA treatment
induced epileptiform discharges without PILO applica-
tion. With respect to suppressing seizure activity and
increasing neuronal survival by Cr (Cr-like compound)
feeding [20,21], our findings suggest that reduced BCK
immunoreactivity may be a practical cause of abnormal
discharge rather than an indicative of a compensatory
consequence of seizure activity, and that maintenance of
Cr-PCr/CK circuit by BCK may play an important role
in increasing acute/initial seizure threshold.
In the present study, uMtCK immunoreactivity was
markedly reduced in CA1-3 pyramidal cells and hilar
Figure 4 The effect of saline (A), GPA (B), Tat-BCK (C) or Cr (D) on latency of PILO-induced seizures. (A-D) Representative field potential
recordings. (E) The histograms of pooled data showing the latency of PILO-induced seizures. GPA treatment induces spontaneous seizure activity
without PILO injection. Significant differences from the controls, *P < 0.05 (paired Student’s t-test).
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immunoreactivity was similar to that observed in control
animals. Furthermore, Cr-, GPA and tat-BCK treatment
could not change EEG patterns or RMS values. Vielha-
ber et al. [61] reported that Cr feeding has deleterious
effects on pyramidal cell survival in the PILO model of
temporal lobe epilepsy, since mitochondrial enzyme
activities are decreased in epileptic rats and Cr feeding
induces more significant decrease in mitochondrial
enzyme activities. With respect to this previous study,
the present data demonstrating the ineffectiveness of
Cr-, GPA and tat-BCK on EEG in epileptic rats are not
surprising. Although the exact biological mechanism
is unclear, furthermore, the phenomenon may be a
Figure 5 Changes in uMtCK (A), BCK (B) and CRT (C) immunoreactivity in the hippocampus of chronic epilepsy rat.u M t C K
immunoreactivity is markedly reduced in CA1-3 pyramidal cells and hilar neurons due to massive neuronal loss. In contrast, BCK
immunoreactivity is similar to that observed in control animals. CRT immunoreactivity is markedly reduced in CA3 pyramidal cells. However, CRT
immunoreactivity is detected in reactive astrocytes within the hippocampus. Rectangles in panels 1 indicate the regions of panels 2 and 3. Bar =
200 (panel 1) and 25 (panels 2-4) μm. (D-E) Double immunofluoresent staining for GFAP (green) and CRT (red) in the CA1 subfield of non-SE (D)
and chronic epileptic rats (E). Arrows indicate the colocalization of CRT and GFAP immunoreactivity. Bar = 50 μm.
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dative phosphorylation in epileptic hippocampus [61].
Further detailed studies are needed to elucidate the
roles of Cr and its metabolism in spontaneous seizure
activity of chronic epileptic rats.
CRT expresses in neurons and oligodendroglia in phy-
siological condition. Under physiological conditions,
therefore Cr can cross from blood to brain through the
blood-brain barrier (BBB) [15], but with a low perme-
ability [29], partly because astrocytes lining the BBB do
not express CRT [62-64]. However, Acosta et al. [65]
reported the localization of CRT in perivascular astro-
cytes within mouse retina. Furthermore, Braissant et al.
[66] have recently reported that NH4Cl induced CRT
expression in astrocytes, including the swollen astro-
cytes that develop during NH4
+ exposure. Therefore,
they suggested that the Cr level-dependent CNS gene
regulation for CRT depends on the cell types considered
and the pathological state of the brain. Similarly, the
present study revealed that CRT expression was
observed in reactive hypertrophic astrocytes in the hip-
pocampi of epileptic rats, while CRT immunoreactivity
was markedly reduced in CA3 pyramidal cells. There-
fore, our findings support that CRT may express in
astrocytes in pathological condition, although CRT
expression in astrocytes is rarely detected in the brain
under physiological condition. Indeed, the properties of
reactive astrocyte are different from those of naive
astrocyte [34,35,38,50] Taken together with preservation
of BCK expression in reactive astrocytes, our findings
suggest that maintenance of Cr-PCr/CK circuit in reac-
tive astrocytes may be involved in migration, prolifera-
tion and differentiation of reactive astrocytes in
epileptic hippocampus described in previous studies
[34,38,50].
Conclusion
In the present study, uMtCK immunoreactivity was
markedly reduced in the hippocampi of chronic epilepsy
rats as compared to control animals, while BCK immu-
noreactivity was similarly observed as that of controls.
In addition, CRT immunoreactivity was increased in
reactive astrocytes, while its immunoreactivity was sig-
nificantly decreased in neurons. These findings would
be simply interpreted that impaired CRT or CK func-
tions may result in imbalance of Cr-PCr/CK circuit in
chronic epilepsy animals. However, Cr-, GPA and tat-
BCK treatment could not affect EEG patterns in chronic
epilepsy rat. Therefore, our findings suggest that, unlike
acute seizure, Cr-PCr/CK circuit may not play a role in
sustaining or exacerbating spontaneous seizure activity
in the epileptic hippocampus.
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